MIRABEGRON IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME RESULTS FROM A NORTH-AMERICAN STUDY

被引：2
|
作者：
Nitti, Victor
Herschorn, Sender
Auerbach, Stephen
Martin, Nancy
Blauwet, Mary Beth
Marshall, Thomas
机构：
来源：
JOURNAL OF UROLOGY | 2011年 / 185卷 / 04期
关键词：
D O I：
10.1016/j.juro.2011.02.2163
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1959
引用
下载
收藏
页码：E784 / E784
页数：1
相关论文
共 50 条
  • [1] THE EFFICACY AND SAFETY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME - RESULTS FROM A NORTH-AMERICAN PHASE III TRIAL
    Nitti, V
    Herschorn, S.
    Auerbach, S.
    Ayers, M.
    Lee, M.
    Martin, N.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 278 - 278
  • [2] Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial
    Roberts, R.
    Bavendam, T.
    Glasser, D. B.
    Carlsson, M.
    Eyland, N.
    Elinoff, V.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (06) : 752 - 758
  • [3] Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
    Carlson, Kevin V.
    Rovner, Eric S.
    Nair, Kavita V.
    Deal, Anna S.
    Kristy, Rita M.
    Schermer, Carol R.
    ADVANCES IN THERAPY, 2019, 36 (08) : 1906 - 1921
  • [4] Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
    Kevin V. Carlson
    Eric S. Rovner
    Kavita V. Nair
    Anna S. Deal
    Rita M. Kristy
    Carol R. Schermer
    Advances in Therapy, 2019, 36 : 1906 - 1921
  • [5] The Potent and Selective beta3-adrenoceptor Agonist Mirabegron Improves Patient-Reported Outcomes in the Treatment of Overactive Bladder
    Khullar, V
    Amarenco, G.
    Angulo, J.
    Boerrigter, P.
    Blauwet, M.
    Hakimi, Z.
    UROLOGY, 2012, 80 (03) : S123 - S123
  • [6] Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study
    Frankel, Jeffrey
    Varano, Susann
    Staskin, David
    Shortino, Denise
    Jankowich, Rachael
    Mudd, Paul N., Jr.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (05)
  • [7] Patient-reported outcomes with the 3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder
    Khullar, Vik
    Amarenco, Gerard
    Angulo, Javier C.
    Blauwet, Mary Beth
    Nazir, Jameel
    Odeyemi, Isaac A.
    Hakimi, Zalmai
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 (08) : 987 - 994
  • [8] Patient-reported outcomes in overactive bladder - Introduction
    Brubaker, Linda
    Chapple, Christopher
    UROLOGY, 2006, 68 (2A) : 1 - 2
  • [9] Tolterodine improves patient-reported outcomes in sexually active women with overactive bladder
    Rogers, Rebecca
    Scarpero, Harriette
    Bachmann, Gloria
    Sun, Franklin
    Morrow, Jon D.
    Bavendam, Tamara
    OBSTETRICS AND GYNECOLOGY, 2008, 111 (04): : 60S - 60S
  • [10] THE POTENT AND SELECTIVE B3-ADRENOCEPTOR AGONIST MIRABEGRON IMPROVES PATIENT-REPORTED OUTCOMES IN OVERACTIVE BLADDER-RESULTS FROM TWO PHASE III STUDIES
    Nitti, V
    Herschorn, S.
    Auerbach, S.
    Khullar, V
    Amarenco, G.
    Blauwet, M. B.
    Boerrigter, P.
    Hakimi, Z.
    Siddiqui, E.
    Martin, N.
    NEUROUROLOGY AND URODYNAMICS, 2012, 31 (06) : 813 - 815
12345